Julien Dilly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julien Dilly has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Aguirre
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
186 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
143 shared publications - Srivatsan Raghavan
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
140 shared publications - Jonathan Andrew Nowak
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA
139 shared publications - Kevin S. Kapner
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
139 shared publications - Andrew D. Cherniack
Broad Institute of MIT and Harvard, Cambridge, MA, USA
118 shared publications
Latest Publications
- 30 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (869)
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non–small cell lung cancer
KRAS G12C (Gly 12 →Cys) inhibitors (G12Cis) have improved outcomes for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), but their clinical benefit is limited by the emergence of resistance mechanisms. Here, we demonstrate that combining the RAF/MEK clamp avutometinib and the focal adhesion kinase (FAK) inhibitor defactinib with a G12Ci enhanced antitumor activity by deepening mitogen-activated protein kinase (MAPK) pathway suppression and simultaneously inhibiting adaptive resistance pathways induced by G12Ci and avutometinib treatment, including FAK and PI3K signaling. In KRAS G12C NSCLC mouse models, the triplet combination produced greater tumor growth inhibition than either sotorasib alone or the sotorasib plus avutometinib doublet. Moreover, in KRAS G12C NSCLC mouse models resistant to sotorasib, the addition of avutometinib and FAK inhibition restored sensitivity to sotorasib and increased both the depth and durability of antitumor responses. Collectively, these findings demonstrate that concurrent targeting of KRAS G12C, RAF/MEK, and FAK signaling can overcome multiple resistance mechanisms and provide a strong rationale for the clinical evaluation of sotorasib, avutometinib, and defactinib in patients with KRAS G12C–mutated NSCLC (RAMP 203; NCT05074810).
- 30 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (869)
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non–small cell lung cancer
KRAS G12C (Gly 12 →Cys) inhibitors (G12Cis) have improved outcomes for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), but their clinical benefit is limited by the emergence of resistance mechanisms. Here, we demonstrate that combining the RAF/MEK clamp avutometinib and the focal adhesion kinase (FAK) inhibitor defactinib with a G12Ci enhanced antitumor activity by deepening mitogen-activated protein kinase (MAPK) pathway suppression and simultaneously inhibiting adaptive resistance pathways induced by G12Ci and avutometinib treatment, including FAK and PI3K signaling. In KRAS G12C NSCLC mouse models, the triplet combination produced greater tumor growth inhibition than either sotorasib alone or the sotorasib plus avutometinib doublet. Moreover, in KRAS G12C NSCLC mouse models resistant to sotorasib, the addition of avutometinib and FAK inhibition restored sensitivity to sotorasib and increased both the depth and durability of antitumor responses. Collectively, these findings demonstrate that concurrent targeting of KRAS G12C, RAF/MEK, and FAK signaling can overcome multiple resistance mechanisms and provide a strong rationale for the clinical evaluation of sotorasib, avutometinib, and defactinib in patients with KRAS G12C–mutated NSCLC (RAMP 203; NCT05074810).
- Top Cited PapersOpen Access
- 11 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2865-2877
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma (PDAC), providing the basis for confirmatory evaluation in the randomized phase 3 RASolute 302 clinical trial. Here we report mechanisms of acquired resistance to daraxonrasib monotherapy observed through targeted sequencing of over 800 genes in paired pretreatment and end of treatment circulating tumor DNA samples from 44 patients in the phase 1/2 clinical trial. Treatment-emergent genomic alterations in the RAS signaling pathway were observed in more than half (26 of 44; 59%) of these patients, including, most notably, mutant KRAS amplifications in one-third (16 of 44; 36%), as well as alterations in receptor tyrosine kinase (RTK) (4 of 44; 9%), MAPK (11 of 44; 25%) and PI3K (4 of 44; 9%) pathways. Notably, no acquired secondary KRAS mutations were observed, distinct from resistance profiles of mutant-selective KRAS G12C(OFF) inhibitors. To corroborate these clinical findings, we found, or mechanistically established, concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC, including mutant KRAS and MYC amplification and RTK upregulation, with these alterations guiding various combination therapy concepts. Notably, daraxonrasib combined with agents targeting DNA damage response, RTKs or the mutant-selective RAS(ON) G12D inhibitor zoldonrasib averted resistance in preclinical models. Collectively, these results show that most daraxonrasib genomic resistance mechanisms drive reactivation of RAS pathway signaling and guide potential combination strategies in PDAC for further investigation.
- 11 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2865-2877
Top Cited PapersOpen AccessAcquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma (PDAC), providing the basis for confirmatory evaluation in the randomized phase 3 RASolute 302 clinical trial. Here we report mechanisms of acquired resistance to daraxonrasib monotherapy observed through targeted sequencing of over 800 genes in paired pretreatment and end of treatment circulating tumor DNA samples from 44 patients in the phase 1/2 clinical trial. Treatment-emergent genomic alterations in the RAS signaling pathway were observed in more than half (26 of 44; 59%) of these patients, including, most notably, mutant KRAS amplifications in one-third (16 of 44; 36%), as well as alterations in receptor tyrosine kinase (RTK) (4 of 44; 9%), MAPK (11 of 44; 25%) and PI3K (4 of 44; 9%) pathways. Notably, no acquired secondary KRAS mutations were observed, distinct from resistance profiles of mutant-selective KRAS G12C(OFF) inhibitors. To corroborate these clinical findings, we found, or mechanistically established, concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC, including mutant KRAS and MYC amplification and RTK upregulation, with these alterations guiding various combination therapy concepts. Notably, daraxonrasib combined with agents targeting DNA damage response, RTKs or the mutant-selective RAS(ON) G12D inhibitor zoldonrasib averted resistance in preclinical models. Collectively, these results show that most daraxonrasib genomic resistance mechanisms drive reactivation of RAS pathway signaling and guide potential combination strategies in PDAC for further investigation.
- Top Cited PapersOpen Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8132) , 789-799
A dependency map enhanced with next-generation 3D cancer models
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8132) , 789-799
Top Cited PapersOpen AccessA dependency map enhanced with next-generation 3D cancer models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Mutation and sequence alterations from whole exome sequencing of in vitro models of acquired resistance to MRTX1133.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Mutation and sequence alterations from whole exome sequencing of in vitro models of acquired resistance to MRTX1133.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRASG12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRASG12D cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRASG12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRASG12D cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Characterization of acquired resistance to KRASG12C inhibition across studies and cancer types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Characterization of acquired resistance to KRASG12C inhibition across studies and cancer types.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 9 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of reagents and antibodies used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 9 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of reagents and antibodies used in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
MRTX1133 sensitivty across the PRISM cohort of cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
MRTX1133 sensitivty across the PRISM cohort of cell lines.